A Rollover Protocol of Dacomitinib For Patients In Japan
NCT02382796
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
Dacomitinib
Sponsor
Pfizer